



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

MASTER'S THESIS

**Inhibitory Effects of *Ganoderma lucidum* Spore Oil
on Rheumatoid Arthritis in a Collagen-Induced
Arthritis Mouse Model**

Yunji Heo

**Department of Animal Biotechnology, Faculty of Biotechnology,
College of Applied Life Sciences**

**GRADUATE SCHOOL
JEJU NATIONAL UNIVERSITY**

February 2023

Inhibitory Effects of *Ganoderma lucidum* Spore Oil on Rheumatoid Arthritis in a Collagen-Induced Arthritis Mouse Model

Yunji Heo

(Supervised by professor Young-Ok Son)

A thesis submitted in partial fulfillment of the requirement for the degree
of Master of Science.

February 2023


This thesis has been examined and approved by



Thesis director, Kyoung-Tag Do, Prof. of Animal Biotechnology, Jeju National University



Inhae Kang, Prof. of Food Science and Nutrition, Jeju National University



Young-Ok Son, Prof. of Animal Biotechnology, Jeju National University

February 2023

Department of Animal Biotechnology, Faculty of Biotechnology,
College of Applied Life Sciences
GRADUATE SCHOOL
JEJU NATIONAL UNIVERSITY



CONTENTS

국문 초록	2
LIST OF FIGURES.....	3
ABSTRACT	4
I. INTRODUCTION	5
II. MATERIALS AND METHODS.....	8
2.1 Reagents and laboratory supplies.....	8
2.2 Preparation of GLS oil extracts by supercritical CO ₂	8
2.3 Analysis of GLS oil by gas chromatography-mass spectrometry (GC-MS)	10
2.4 Experimental RA model generation and von Frey and hot-plate assays	11
2.5 GLS oil injection	11
2.6 Clinical score & paw thickness	11
2.7 Histological examinations.....	12
2.8 Immune cell infiltration analysis.....	12
2.9 Cell culture and treatment.....	13
2.10 Quantitative real-time RT-PCR based analysis.....	13
2.11 Immunohistochemistry Analysis	14
2.12 Statistical analysis.....	14
III. RESULTS.....	15
3.1 Extraction and identification of GLS components	15
3.2 Effects of GLS oil on clinical scores, paw thickness, and pain in a RA model	16
3.3 Effect of GLS oil on cartilage degeneration in mice knees, ankles, and soles in a CIA-induced RA model	18
3.4 GLS oil attenuates immune cell infiltration in a CIA-induced RA model	24
3.5 Effect of GLS oil administration in IL-6 expression in vitro and in vivo	27
IV. DISCUSSTION	29
V. CONCLUSION.....	32
VI. REFERNCES	33

국문 초록

몇몇의 의료 종사자들은 RA를 치료하기 위해 특정 약용 버섯에 초점을 맞추기 시작했습니다. 그 중 *Ganoderma lucidum*(GL)은 고대 중국 의학에서 RA와 같은 자가 면역 질환을 포함한 염증성 질환을 치료하는 데 사용된 가장 오래된 버섯 중 하나로 알려져 있습니다. 이 버섯의 포자는 면역 조절, 노화 및 암에 특정한 영향을 미칩니다. 그러나 *G. lucidum* spore(GLS)의 관절염에 대한 효과는 아직 명확하게 밝혀지지 않았습니다. 따라서 콜라겐 유발 류마티스 관절염(CIA) 모델을 활용하여 GLS 오일이 관절염에 주는 효과를 조사하였습니다. GLS오일의 성분 분석에 따르면 GLS 오일에는 10가지 산이 포함되어 있으며 그 중 올레산(52.12%)과 리놀레산(16.77%)이 상당부분을 차지하고 있습니다. GLS 오일을 주입한 CIA 그룹은 일반 CIA 그룹보다 RA에 대해 유의적으로 더 낮은 중증도 점수($p = 0.0384$)를 보였습니다. 또한, GLS 오일은 관절에서 CIA에 의해 유발된 연골 변성과 활막에서의 염증을 감소시켰으며 그리고 CIA에 의해 유발된 판누스 형성도 감소시켰습니다. 이와 더불어 면역세포 활성화 측면에서도 GLS 오일을 주입한 그룹은 관절에서의 호산구의 증가정도가 유의하게 감소하였고($p = 0.0056$), 호중구의 침윤을 확인한 결과 호중구의 침윤정도가 무릎($p = 0.0006$)과 발목($p = 0.0023$) 모두 GLS 오일을 주입한 그룹에서 유의하게 감소했습니다. 이러한 결과는 GLS 오일이 RA 약물 개발에 유용할 수 있음을 시사하고 이와 관련된 GLS오일의 더 높은 개선효과를 확인하기 위해서는 추가 임상 연구가 필요합니다.

LIST OF FIGURES

Figure 1. Extraction and identification of GLS components.....	9
Figure 2. The effects of <i>Ganoderma lucidum</i> spore (GLS) oil on the clinical score of a collagen-induced arthritis (CIA) model.	16
Figure 3. <i>Ganoderma lucidum</i> spore (GLS) oil attenuates pain in the collagen-induced arthritis (CIA) model.....	17
Figure 4. <i>Ganoderma lucidum</i> spore (GLS) oil attenuates cartilage destruction, synovitis, and pannus formation of the knee in a collagen-induced arthritis (CIA) model.....	19
Figure 5. <i>Ganoderma lucidum</i> spore (GLS) oil attenuates cartilage destruction, synovitis, and pannus formation of the ankle in a collagen-induced arthritis (CIA) model.....	21
Figure 6. <i>Ganoderma lucidum</i> spore (GLS) oil attenuates cartilage destruction, synovitis, and pannus formation of the sole in a collagen-induced arthritis (CIA) model.....	23
Figure 7. <i>Ganoderma lucidum</i> spore (GLS) oil attenuates immune cell activation in a collagen-induced arthritis (CIA) model.	25
Figure 8. <i>Ganoderma lucidum</i> spore (GLS) oil attenuates IL-6 expression in RA conditions.	28

ABSTRACT

Holistic healthcare practitioners have now started to focus on specific traditional medicinal mushrooms to treat rheumatoid arthritis (RA). *Ganoderma lucidum* (GL) is one of the oldest mushrooms that have been used in ancient Chinese medicine to treat inflammatory ailments, including autoimmune diseases such as RA. Spores from this mushroom have specific effects on immunomodulation, aging, and cancer. However, the effect of *G. lucidum* spores (GLS) on arthritis remains unclear. Therefore, we investigated the effects of GLS oil in a collagen-induced rheumatoid arthritis (CIA) model. Metabolomics analysis revealed that GLS oil contains ten acids, of which oleic acid (52.12%) and linoleic acid (16.77%) predominated. The GLS oil-treated CIA mice had a significantly lower clinical score ($p = 0.0384$) for RA than the control CIA mice. Moreover, GLS oil reduced CIA-induced cartilage degeneration and synovial membrane inflammation in the knee. The GLS oil group showed significantly reduced knee eosinophilia ($p = 0.0056$). Immunostaining of neutrophils revealed that neutrophils infiltrated the CIA group; however, infiltrated neutrophils were significantly reduced in the GLS oil group in both the knees ($p = 0.0006$) and ankles ($p = 0.0023$). GLS oil treatment substantially suppressed LPS- or TNF- α -induced IL-6 mRNA expression in primary cultured chondrocytes. IL-6 immunohistochemistry results showed that the protein levels of IL-6 were attenuated in the GLS oil group compared to the CIA group. These findings suggest that GLS oil may be useful for the development of RA drugs. Further clinical research is required to identify significant improvements.

Keywords: Supercritical carbon dioxide, *Ganoderma lucidum* spores, Rheumatoid arthritis, Collagen-induced rheumatoid arthritis

I. INTRODUCTION

Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease that affects 0.5–1.0% of the world population [1]. It is a chronic condition that causes joint swelling, stiffness, and immunosenescence. The latter appears to be a major contributor to the increased risk of disability in elderly patients with RA [2]. Moreover, RA has a high incidence of complications, such as cardiovascular disease and osteoporosis, due to its direct and indirect effects on other systemic symptoms and inflammation [3]. Genetics, infectious diseases, environmental variables, and hormonal influences are all factors that contribute to RA [2]. Additionally, research indicates that the pathogenesis of RA is influenced by interactions and the activation of innate and adaptive immune cells [2, 3]. However, the underlying mechanisms of RA remain unknown.

Disease-modifying antirheumatic drugs (DMARDs) are used to prevent joint damage during the early stages of RA. Anti-rheumatic drugs are sometimes used to bring about remission or slow the progression of RA [3]. These medications include methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide. High doses of these drugs can cause gastrointestinal irritation and other side effects, which can lead to the development of ulcers and perforations in some cases [4]. Liver and kidney damage caused by arthritis medication can also cause skin rashes, urticaria, headache, dizziness, and drowsiness, with some patients experiencing hypertension and edema [5]. Thus, finding effective alternative medicines with fewer side effects is critical.

Ganoderma lucidum (GL) is an annual mushroom that grows on hardwoods in the summer and has a strong bitter taste, and is known as 'Ling zhi' in China and 'Rei shi' in Japan [6]. GL spores (GLS) are discharged from GL in the form of brown ovals. For over 2,000 years, GL has been used as a medicinal mushroom for heart function, memory enhancement, and anti-aging. Organic germanium GL is recommended for cough and asthma relief, dizziness,

insomnia, and breathing difficulties [7]. The physiologically active substances of the GL fruiting body include beta-glucan, sterols, triterpenes, and selenium. The spores of GL have a higher bioactivity than the fruiting body [8] and have been recognized as a promising drug due to their versatile biological activity [9]. The physiologically active substances of GLS include polysaccharides, triterpenoids, peptides, amino acids, fatty acids, and trace elements [10-12]. These biologically active substances have immune regulation, anti-aging, blood lipid reduction, antiviral, and anticancer properties [13]. A plethora of studies have investigated the anti-cancer, anti-pain, and immune-enhancing properties of the fruit and mycelium of GL. However, the efficacy of GLS oil in RA remains to be demonstrated.

The application of natural derivatives (e.g., bioactive compounds) in the pharmaceutical, food, and cosmetic industries, is becoming more commonplace [14-16]. Generally, bioactive compounds are extracted from natural sources using conventional methods, and then fractionated or isolated further. However, many of these methods use organic solvents, which are hazardous to the environment and human health [17, 18]. Moreover, economic systems and government agencies are increasingly demanding safer products for humans and the environment, and that they are produced in a clean, non-polluting manner [19]. CO₂ is non-flammable, non-toxic, inexpensive, and of high purity, with moderate critical pressure and temperature [15]. Although CO₂ lacks the polarity required to extract polar substances, this disadvantage can be overcome using a co-solvent such as a short-chain (sc) alcohol [20]. sc-CO₂ allows for effective and rapid extraction because it can be easily and completely removed by lowering the pressure, at which point it turns into gas [20]. Supercritical fluid technology has received considerable attention as an environmentally friendly and widely applicable method for producing or micronizing pharmaceutical compounds and bioactive compounds [20, 21]. This technology has grown in popularity and is now widely used for extraction, fractionating, and isolation of bioactive compounds from plants and animals.

This study explored the remission effects of GLS in RA. The GLS compounds were

extracted using supercritical CO₂, an extraction method that does not require toxic solvents. Furthermore, we examined the ameliorative effects of GLS oil on RA in the collagen-induced rheumatoid arthritis (CIA) mouse model.

II. MATERIALS AND METHODS

2.1. Reagents and laboratory supplies

Chemicals and Falcon Labware were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Laboratory equipment were obtained from Becton-Dickinson (Franklin Lakes, NJ, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), and recombinant human IL-6 (PHC0064) were purchased from Thermo Fisher Scientific (Grand Island, NY, USA).

2.2. Preparation of GLS oil extracts by supercritical CO₂

GLS oil was extracted using the supercritical CO₂ extraction methods [22]. Figure 1a shows a schematic of the extraction apparatus manufactured by Nantong Wisdom Supercritical Science and Technology Development Co., Ltd. (China). The system comprises a 5 L extractor, two separators (separator 1: 3 L, separator 2: 2 L), a chiller, and a high-pressure CO₂ pump, which delivers the CO₂ from the CO₂ cylinder into the system. All the vessels were heated using heating jackets. In a typical experiment, 2 kg of powdered GLS were loaded into the extractor and a certain amount of was CO₂ pumped into the system. Next, valve 9 (V9) was opened to empty the system. Purging with CO₂ was repeated three times to replace the air in the system. After purging, all valves were closed, except for V1 and V2, to allow a certain amount of CO₂ to be pumped into the extractor. After the pressure and temperature of the extractor reached 40 MPa and 55 °C, V5, V8, and V11 were opened for CO₂ circulation and dynamic extraction. The temperature and pressure of separators 1 and 2 were set at 50 °C, 13 MPa, and 40 °C, 5 MPa, respectively. The CO₂ mass flow rate was maintained at 35 kg/h and the extraction process lasted for 2 h. After completing the extraction, the GLS oil was collected via V7 and stored for later testing.




Figure 1. (a) Schematic diagram of the supercritical extraction apparatus. (b) Gas chromatography–mass spectrometry chromatogram for the supercritical CO₂ extracted *Ganoderma lucidum* spore (GLS) oil. (c) Compound list and corresponding percentages of

chemicals in *Ganoderma lucidum* spore (GLS) oil extracted using supercritical CO₂ fluid.

2.3. Analysis of GLS oil by gas chromatography–mass spectrometry (GC-MS)

The samples were converted to the corresponding fatty acid methyl ester (FAMES) according to a previously published method [23]. Total fatty acids and fatty acid contents in the oil samples were measured concurrently in two steps: (1) preparation of FAME (2) and chromatographic analysis. One hundred microliters of GLS were added to a test tube with a stopper and 4 mL of potassium hydroxide/methanol solution (0.5 M) was added. The mixture was combined and allowed to evaporate for 15 minutes in a rotary evaporator. Subsequently, 1.6 mL of methanol:hydrochloric acid was added, and the sample was stirred for another 10 minutes, followed by the addition of 6 mL of n-hexane to the sample. This was mixed well until the two layers were separated. The upper layer of n-hexane was extracted to recover the methyl esters in the organic phase into a new test tube. After a certain amount of anhydrous sodium sulfate was added to the n-hexane for dehydration, the mixture was allowed to stand for clarification. The supernatant was analyzed by GC-MS on a Shimadzu QP2010 SE gas chromatography-mass spectrometer (Shimadzu, Kyoto, Japan) equipped with a DB-FFAP (25 m × 0.32 mm × 0.5 μm) column (Agilent, United States). The injector temperature was set to 250 °C and the column temperature from 50–240 °C; the initial column temperature was 50 °C and was held for 2 min, next, the temperature was ramped to 180 °C at a rate of 10 °C/min, and held for 5 min, and then finally increased to 240 °C at a rate of 5 °C/min, and held 25 min. Fatty acid methyl esters were separated and the peaks were identified by comparing the mass spectra with the mass spectral library database.

2.4. Experimental RA model generation and von Frey and hot-plate assays

All experiments were conducted with the permission of the Institutional Animal Care and Committee of Jeju National University (2022-0002). Seven-week-old DBA/1 J mice were used for constructing the experimental RA model. Under isoprene anesthesia, equal volumes of collagen type II and 4 mg/mL of total Freund's adjuvant were prepared and slowly injected into their tails [24, 25].

The von Frey test was conducted once weekly after seven days of arthritis induction. Briefly, the stab of the filament started with a thick size on the sole and was recorded when the mice were licking. Each stab was performed five times and licking was recorded three times. If the mice did not react, the filament was changed to a lower filament and processed for further analysis [26]. The hot-plate assay was performed using the Plantar Test for Thermal Stimulation-Hargreaves Apparatus (ugo basile®, 37570, Gemonio, Italy). The experimental mouse was placed at five different locations, and the patience time (in seconds) when the mouse was removed from the soleplate was recorded. When the mouse licked or popped, the reaction time was recorded for accurate measurements. Each leg was measured five times, and the average values were recorded [27, 28].

2.5. GLS oil injection

GLS oil was injected one week after CIA induction. The GLS oil (6 mg/Kg) was mixed with polyethylene glycol 400 (PEG-400) and intraperitoneally injected (200 μ L) twice a week for seven weeks, while 200 μ L of PEG-400 was injected in the control group.

2.6. Clinical score & paw thickness

From the first day of intraperitoneal GLS injection, the hind paws of the mice on both sides were examined every 3–4 days, and the severity was determined by the amount of swelling. The CIA scoring index developed by Hooke Laboratories was used to grade the

severity of arthritis (0–4) as follows: an uninflamed, normally functioning foot; one or both toes are inflamed and swollen, while the foot or ankle is not necessarily visibly swollen; two or more toes are inflamed and swollen, but the entire foot may not be swollen or may only have mild swelling; three or all four toes may be severely swollen, preventing the mice from grasping the top of the cage [29]. The most severe swelling in the mouse ankle was measured every 3 or 4 days following the intraperitoneal GLS injection. After seven weeks, the experimental mice were euthanized with CO₂, and knee, ankle, and sole tissues were collected for histological analyses.

2.7. Histological examinations

The collected tissues were fixed in 4% paraformaldehyde for 24 h and then decalcified for two weeks in 0.5 M ethylenediaminetetraacetic acid (pH 7.4). The tissues were sectioned to a thickness of 4 µm for slide preparation after dehydration. A block was created by fixing it in paraffin [30, 31]. Harris hematoxylin, Fast Green, and Safranin O (Sigma-Aldrich, St. Louis, MO, USA) were used for histological analyses. The histological degree of inflammation in RA was classified into three categories: OARSI (Osteoarthritis Research Society International) grade (0–6), synovitis score (0–3), and pannus score (0–4). Five observers evaluated the OARSI, synovitis, and pannus scores. The scoring results were calculated by averaging the scores of the observers for each mouse. A representative image of Safranin-O with the most representative etiology among the sections was chosen.

2.8. Immune cell infiltration analysis

Congo red (Sigma C6277, St. Louis, MO, USA) and Toluidine blue O (Sigma Cat.no, St. Louis, MO, USA) were used for eosinophils and mast cell staining, respectively. The infiltration of eosinophils and mast cells into the synovial membrane around the joint was analyzed. CD15 was used for neutrophil extracellular traps, and the quantification of

neutrophils was analyzed using ImageJ [32].

2.9. Cell culture and treatment

Chondrocytes were isolated and cultured following trypsin and collagenase digestion [33, 34]. Primary chondrocytes ($3 \times 10^5/30$ mm culture dish) were treated with different concentrations of GLS (0-300 g/ml) in the presence or absence of LPS (10 ng/ml) or TNF- α (10 ng/ml). The samples were then subjected to quantitative real-time RT-PCR (qRT-PCR) analysis.

2.10. qRT-PCR-based analysis

Total RNA was extracted from primary cultured chondrocytes using the TRIzol reagent (Molecular Research Center, Inc., Cincinnati, OH, USA). The NanoDropTM 2000 spectrophotometer was used to check RNA integrity and concentration (Thermo Scientific, Waltham, MA, USA). Following cDNA synthesis, qRT-PCR analysis for IL-6 expression was conducted on the BIO-RAD Real-Time PCR instrument (CFX96TM Real-Time System, Bio-Health Materials Core-Facility, Jeju National University) using the SYBR premixed Extaq solution (Takara Bio, Mountain View, CA, USA). Relative gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase(GAPDH) levels. Forward: 5'-TCTA TACCACTTCACAAGTCGGA-3', reverse: 5'-GAATTGCCATTGCACAACCTCTTT-3' and forward: 5'-TCACTGCCACCC AGAAGAC-3', reverse: 5'-TGTAGGCCATGAGGTCCA C-3' were IL-6 and GAPDH primer sequences, respectively.

2.11. Immunohistochemistry analysis

Hydroperoxide (Dako LSAB2 System-HRP Kit; Dako REAL; Agilent, Santa Clara, CA, USA) was used to inhibit the endogenous peroxidase activity of the cartilage and synovium before antigen retrieval with 0.05% trypsin. The slides were blocked in 1% bovine serum albumin before incubation at 4 °C for 12–16 hours with a rabbit monoclonal antibody against IL-6 (1:200 dilution, #12912; Cell signaling, Danvers, MA, USA). The slides were stained with Dako Real Envison™ after incubation with a secondary anti-rabbit antibody for 1 hour at 20 °C (K5007, Santa Clara, CA, USA).

2.12. Statistical analysis

Statistical analyses were performed using IBM SPSS Statistics 24 (IBM Corp., Armonk, NY, USA). The data were analyzed by analysis of variance (ANOVA) for determining the relative quantitative gene expressions by real-time qRT-PCR. The results of the histological experiments were analyzed using the Mann-Whitney U test. Significant differences between the means were analyzed at $p < 0.05$ by Student's t-test.

III. RESULTS

3.1. Extraction and identification of GLS components

From the 2 kg of powdered GLS, the GLS oil yield was 600 g. Results of the GC-MS analysis of the GLS oil are shown in Figure 1b. The GLS oil was found to be composed of oleic acid (52.12%), linoleic acid (16.77%), palmitate acid (13.67%), elaidic acid (9.16%), palmitoleate acid (2.95%), stearate acid (1.58%), palmitic acid (1.35%), fatty acid methyl ester (1.01%), stearic acid (0.87%), and pentadecanoic acid (0.52%) (Figure 1c).

3.2. Effects of GLS oil on clinical scores, paw thickness, and pain in a RA model

The GLS oil in combination with PEG-400 (6 mg/Kg) was intraperitoneally administered (200 μ L) into the mice twice a week for seven weeks. According to our preliminary animal experiments, 6 mg/kg of GLS oil was an optimal concentration. In the CIA model, administering GLS oil at a dose greater than 6 mg/Kg showed no noticeable significant inhibitory effects. The group treated with GLS oil had a significantly lower severity level than those treated with PEG alone (control). Regarding the clinical RA score, the GLS oil-injected group showed significantly lower severity than the control-injected group ($p = 0.0384$; Figure 2b). Moreover, CIA-induced paw swelling was reduced by GLS oil treatment (Figures 2c and d).




Figure 2. The effects of *Ganoderma lucidum* spore (GLS) oil on the clinical score of collagen-induced arthritis (CIA) model. **(a)** Outline of the experimental plan and animal grouping. Clinical score (0–4) **(b)** and paw thickness **(c)** were measured every three days during the experimental period. **(d)** Differences in paw swelling between the experimental groups.

After 35 days of immunization, the von Frey assay revealed that GLS oil provided pain relief (Figure 3a). Forty-nine days after vaccination, the painkilling effect of GLS oil was found to be significant ($p = 0.0248$). In addition, a hot plate assay showed that, compared with the control group, the CIA group showed significantly reduced latency ($p = 0.03$). GLS oil, however, significantly recovered the CIA-induced decrease in latency ($p = 0.0309$; Figure 3b).




Figure 3. *Ganoderma lucidum* spore (GLS) oil attenuates pain in collagen-induced arthritis (CIA) model. von Frey assays (**a**) and hot plate tests (**b**) for pain responses were performed once a week for seven weeks following immunization.

3.3. Effect of GLS oil on cartilage degeneration in mice knees, ankles, and soles in a CIA-induced RA model

GLS oil treatment reduced CIA-induced synovitis, pannus formation, and cartilage degeneration. Safranin-O staining revealed the degree of cartilage degeneration, synovial membrane inflammation, and inflammation-mediated cell penetration into the bone. GLS oil treatment reduced inflammation of the synovial membrane (Figures 4a and b) and cartilage degeneration in the knee induced by CIA (Figures 4c and d). Moreover, GLS oil treatment lessened the development of panni in the knee induced by CIA (Figures 4e and f).




Figure 4. *Ganoderma lucidum* spore (GLS) oil attenuates cartilage destruction, synovitis, and pannus formation of the knee in collagen-induced arthritis (CIA) model. Cartilage degeneration and erosion were analyzed by OARSI staining (**a**), and the quantification results are shown (**b**). Knee synovitis for inflammation was analyzed by hematoxylin and eosin staining (**c**), and the quantification results shown (**d**). Pannus formation for immune cell penetration to the knee bone is presented in (**e**), and the quantification results are shown (**f**). Abbreviations: OARSI, Osteoarthritis Research Society International.

Safranin-O staining of the ankles showed that erosion of ankle cartilage was reversed by GLS oil treatment (Figure 5a). According to the ankle OARSI grade, GLS oil significantly decreased cartilage damage compared to the CIA group (Figure 5b, $p = 0.0187$). Additionally, GLS oil significantly reduced ankle synovitis ($p = 0.0028$) and synovial membrane inflammation (Figures 5c and d). Finally, GLS oil prevented immune cells from penetrating the bone (Figures 5e and f).




Figure 5. *Ganoderma lucidum* spore (GLS) oil attenuates cartilage destruction, synovitis, and pannus formation of the ankle in collagen-induced arthritis (CIA) model. Cartilage damage to the ankle was visualized by OARSI staining (**a**), and the quantification results shown (**b**). The degree of inflammation in the ankle synovial membrane is presented in (**c**), and the quantification of results are shown (**d**). The degree of inflammatory penetration into the bone was visualized in (**e**), and the quantification results are shown (**f**).

Abbreviations: OARSI, Osteoarthritis Research Society International.

Regarding the sole, GLS oil-treated mice had less cartilage degeneration compared to the PEG-treated mice (Figures 6a and b). The CIA group experienced increased synovial membrane inflammation, whereas the GLS oil-treated group experienced decreased inflammation (Figures 6c and d). Pannus formation was the only variable that showed an increase in the CIA group and was significantly reduced in the GLS oil-treated group (Figures 6e and f).




Figure 6. *Ganoderma lucidum* spore (GLS) oil attenuates cartilage destruction, synovitis, and pannus formation of the sole in collagen-induced arthritis (CIA) model. The degree of cartilage degeneration and damage was visualized by OARSI staining (a), and the OARSI grade was quantified (b). The degree of inflammation in the synovial membrane of the sole (c) and the synovitis scoring is shown (d). The degree of immune cells penetration into the bone (e) and the result of the pannus formation score (f).

3.4. GLS oil attenuates immune cell infiltration in a CIA-induced RA model

Congo red staining revealed eosinophil infiltration in the synovial membranes of the knee and ankle in the CIA group (Figure 7a). The eosinophil count of the knee was significantly reduced in the GLS oil-treated group ($p = 0.0056$). CDr15 immunostaining demonstrated that neutrophils infiltrated the CIA group; however, the infiltrated neutrophils were significantly attenuated in the GLS oil-treated group in both the knee ($p = 0.0006$) and ankle ($p = 0.0023$; Figures 7d-g). The total number of mast cells and degranulated mast cells increased in the CIA group (Figures 7h-j). The number of mast cells decreased in the GLS oil group, but the difference was not statistically significant.




Figure 7. *Ganoderma lucidum* spore (GLS) oil attenuates immune cell activation in collagen-induced arthritis (CIA) model. The eosinophil infiltration in the knee and ankle were analyzed

by Congo red staining **(a)**. The quantification of eosinophil infiltration of the knee and ankle are presented in **(b)** and **(c)**, respectively. In addition, neutrophil penetration of the knee and ankle by CD15 staining is presented in **(d)** and **(e)**. The quantification of eosinophil infiltration of the knee **(f)** and the ankle **(g)** are presented. Finally, mast cell number and activity in the knee and ankle were analyzed by toluidine blue staining **(h)**. The total mast cell number and degranulated mast cells of the knee and ankle are presented in **(i)** and **(j)**, respectively.

3.5. Effect of GLS oil administration on IL-6 expression in vitro and in vivo

To understand the mechanisms of GLS oil action against RA, we analyzed biomarkers for RA. GLS oil treatment impacts IL-6 expression in both in vitro primary cultured chondrocytes and in vivo CIA-induced RA models. GLS oil reduced IL-6 mRNA expression in LPS- or TNF- α -treated primary cultured chondrocytes. (Figures 8a and b). In particular, GLS oil administration significantly reduced LPS-induced IL-6 mRNA expression, stimulated at concentrations of 100 ($p = 0.0003$) to 300 ($p = 0.0019$) $\mu\text{g/ml}$. Moreover, GLS oil significantly inhibited TNF- α -induced IL-6 mRNA expression at 100 ($p = 0.003$) to 300 ($p = 0.0041$) $\mu\text{g/ml}$ concentration. Additionally, immunohistochemistry for IL-6 showed that GLS oil significantly reduced its expression in the cartilage or synovium of the knee and ankle (Figures 8c and d). These findings indicated that in this experiment paradigm, GLS oil specifically downregulated IL-6 expression.




Figure 8. *Ganoderma lucidum* spore (GLS) oil attenuates IL-6 expression in RA. (a)(b) The mRNA expressions of IL-6 in LPS- or TNF- α -exposed chondrocytes after treatment with GLS oil (0 – 300 μ g/ml) for 24 h. In this CIA experimental paradigm, the protein levels of IL-6 were analyzed in the cartilage of the knee and ankle (c) and synovium of the knee and ankle (d).

IV. DISCUSSION

RA is a representative autoimmune disease characterized by chronic inflammation and severe damage to the cartilage and bone; however, the underlying mechanisms remain unknown. Indeed, RA is associated with a higher risk of various health conditions, including inflammation, which incurs extra societal and economic consequences [35-37].

GL has been used as a medicinal mushroom to relieve pain and inflammation for hundreds of years [38]. Triterpenoids, polysaccharides, steroids, and fatty acids comprise the core bioactive components of the GLS [23]. Notably, prior studies revealed that 20–30% of lipids are contained in GLS; accordingly, substantial amounts of long-chain fatty acids and unsaturated fatty acids were found to be essential nutrients for normal growth development with various beneficial effects on human health [39].

Previous studies have shown that oleic acid (60.1–68.4%) and palmitate acid (16.3–21.3%) account for most fatty acids in GLS oil obtained from supercritical extraction. Stearic acid, palmitoleic acid, and linoleic acid, however, comprise the minor compounds of GLS oil [39]. Oleic acid has been reported to be effective in immunity, inflammation, cancer, and wound healing [40], while linoleic acid is known to have anti-inflammatory effects [41, 42]. Our findings are in keeping with those from previous studies of GLS [23]. When GLS is extracted using supercritical CO₂, the amount of oleic acid is generally higher [43]. Our GC-MS results showed that oleic acid (52.12%) and palmitate acid (13.67%) were the major compounds. The beneficial outcomes of GLS may be attributed to the synergic effects of fatty acids and the richness of oleic acid.

In this study, we investigated the effect of supercritical CO₂ extracted GLS oil on arthritis pathogenesis *in vitro* and *in vivo*. The clinical indicators, such as clinical score and paw thickness, were attenuated after GLS oil infusion into the CIA-induced RA model. Moreover, GLS oil attenuated the clinical symptoms of pain in the CIA-induced RA model. The GLS oil-

injected group exhibited much lesser damage to the mice's knee cartilage, less pannus development, and less synovial membrane inflammation. Moreover, compared to the CIA group, the GLS oil group had lower eosinophil, neutrophil, and mast cell activities in the knee and ankle. GLS oil causes apoptosis of breast cancer cells in vitro and in vivo by activating caspase-3 and caspase-9 [11]. It also accelerates the process of skin wound healing [6]. In this study, for the first time, we documented the effect of GLS oil on RA modulates. In addition to significantly reducing clinical arthritic scores, the frequency of clinically evident indications for the use of GLS oil suggests an eventual termination of synovial inflammation and erosive joint deterioration. These findings suggested that GLS therapy may prevent CIA from progressing and/or lessen its severity.

Compared to the CIA-only group, the attenuation rate of neutrophils and eosinophils in the GLS oil group was appreciably higher in the knee and ankle. Neutrophils play a crucial role in congenital immune responses such as RA. IL-6 binds to multiple cell types in the preclinical RA state and induces neutrophil migration into the joints, thus contributing to the progression from acute to chronic inflammation and changes in T/B cell differentiation and angiogenesis [44, 45]. Infiltrating neutrophils reduced markedly in the knee and ankle treated with GLS oil. IL-6 activates neutrophils expressing membrane-bound IL-6R. We expected that GLS oil would suppress IL-6 expression, thus regulating the trigger for neutrophils for the expression of membrane-bound IL-6R [46]. The eosinophils tend to increase in other rheumatic conditions, which is thought to be a sign of disease activity and poor prognosis [47]. Comparing the GLS oil group to the CIA group, mast cell infiltration and activation also showed a slight decrease, even though the rate of decrease was insignificant. Mast cells, one of the cells that make up the innate immune system and are found in tissues, are known to play a role in the pathogenesis of RA [48].

RA patients with elevated levels of cytokines, such as IL-6, present with inflammation, which is an established prognostic indicator of treatment response, tiredness, pain, and

depression [49, 50]. In this experiment, GLS oil reduced IL-6 mRNA expression in response to LPS or TNF- α treatment in primary cultured chondrocytes. GLS oil substantially reduced LPS-induced and TNF- α -induced IL-6 mRNA expressions. The IL-6 expression is increased by various transcription factors, including NF- κ B, which in turn is triggered by other proinflammatory cytokines and TLR-mediated signals [51, 52]. Nevertheless, as stated previously, anti-IL-6R medications have been used against RA for over a decade. However, the widespread use may raise the health risk of associated illnesses, wherein IL-6 is also directly implicated [53, 54]. The GLS oil may therefore be a promising solution as a natural rehabilitation strategy. According to our findings, GLS oil has anti-rheumatic effects with pain-relieving properties that are mediated by the reduction of immune cells in the tissues of the joints.

V. CONCLUSIONS

Using the CIA-induced RA model, we provide here, convincing evidence that GLS oil reduces pannus formation, inflammation, and inflammation-mediated RA pain and swelling. This result suggested that GLS oil-derived substrates might be used in the treatment of inflammatory illnesses such as arthritis. However, existing research has not assessed the effect of individual substances in GLS oil extracts on RA development as well as its regulation for curing and preventing severity. Consequently, additional research is required to determine the impact of individual active substances on RA.

VI. REFERENCES

- [1] J.S. Smolen, D. Aletaha, I.B. McInnes, Rheumatoid arthritis, *Lancet* 388(10055) (2016) 2023-2038.
- [2] B. Jihye, H. Eunyong, H. Jian, Expression of Pain Receptors by Arthritis Treatment in Collagen Induced Murine Model of Rheumatoid Arthritis, *J Rheum Dis* 22(2) (2015) 85-92.
- [3] E.H. Choy, G.S. Panayi, Cytokine pathways and joint inflammation in rheumatoid arthritis, *N Engl J Med* 344(12) (2001) 907-16.
- [4] B. Cryer, K.W. Mahaffey, Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment, *J Multidiscip Healthc* 7 (2014) 137-46.
- [5] X. Wang, X. Chen, W. Huang, P. Zhang, Y. Guo, H. Körner, H. Wu, W. Wei, Losartan suppresses the inflammatory response in collagen-induced arthritis by inhibiting the MAPK and NF- κ B pathways in B and T cells, *Inflammopharmacology* 27(3) (2019) 487-502.
- [6] C. Jiao, Y. Xie, H. Yun, H. Liang, C. He, A. Jiang, Q. Wu, B.B. Yang, The effect of Ganoderma lucidum spore oil in early skin wound healing: interactions of skin microbiota and inflammation, *Aging (Albany NY)* 12(14) (2020) 14125-14140.
- [7] Wachtel-Galor S, Yuen J, Buswell JA, et al. Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom. In: Benzie IFF, Wachtel-Galor S, editors. *Herbal Medicine: Biomolecular and Clinical Aspects*. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 9.
- [8] C.J. Chang, C.S. Lin, C.C. Lu, J. Martel, Y.F. Ko, D.M. Ojcius, S.F. Tseng, T.R. Wu, Y.Y. Chen, J.D. Young, H.C. Lai, Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota, *Nature communications* 6 (2015) 7489.
- [9] S.W. Chan, B. Tomlinson, P. Chan, C.W.K. Lam, The beneficial effects of Ganoderma lucidum on cardiovascular and metabolic disease risk, *Pharm Biol* 59(1) (2021) 1161-1171.
- [10] Y. Liu, G. Lai, Y. Guo, X. Tang, O. Shuai, Y. Xie, Q. Wu, D. Chen, X. Yuan, Protective effect of Ganoderma lucidum spore extract in trimethylamine-N-oxide-induced cardiac dysfunction in rats, *J Food Sci* 86(2) (2021) 546-562.
- [11] C. Jiao, W. Chen, X. Tan, H. Liang, J. Li, H. Yun, C. He, J. Chen, X. Ma, Y. Xie, B.B. Yang, Ganoderma lucidum spore oil induces apoptosis of breast cancer cells in vitro and in vivo by activating caspase-3 and caspase-9, *Journal of Ethnopharmacology* 247 (2020) 112256.
- [12] C. Jiao, H. Yun, H. Liang, X. Lian, S. Li, J. Chen, J. Qadir, B.B. Yang, Y. Xie, An active ingredient isolated from Ganoderma lucidum promotes burn wound healing via TRPV1/SMAD signaling, *Aging (Albany NY)* 14(13) (2022) 5376-5389.

- [13] C. Chen, P. Li, Y. Li, G. Yao, J.H. Xu, Antitumor effects and mechanisms of Ganoderma extracts and spores oil, *Oncology letters* 12(5) (2016) 3571-3578.
- [14] P.A. Uwineza, A. Waśkiewicz, Recent Advances in Supercritical Fluid Extraction of Natural Bioactive Compounds from Natural Plant Materials, *Molecules* 25(17) (2020) 3847.
- [15] O. Wrona, K. Rafińska, C. Możeński, B. Buszewski, Supercritical Fluid Extraction of Bioactive Compounds from Plant Materials, *J AOAC Int* 100(6) (2017) 1624-1635.
- [16] J. Premkumar, R. Thottiam Vasudevan, Bioingredients: functional properties and health impacts, *Current Opinion in Food Science* 19 (2018) 120-128.
- [17] S. Bourgou, I. Bettaieb Rebey, S. Dakhlaoui, K. Msaada, M. Saidani Tounsi, R. Ksouri, M.L. Fauconnier, I. Hamrouni-Sellami, Green extraction of oil from *Carum carvi* seeds using bio-based solvent and supercritical fluid: Evaluation of its antioxidant and anti-inflammatory activities, *Phytochem Anal* 31(1) (2020) 37-45.
- [18] K.K. Pulicherla, V. Adapa, M. Ghosh, P. Ingle, Current efforts on sustainable green growth in the manufacturing sector to complement “make in India” for making “self-reliant India”, *Environmental Research* 206 (2022) 112263.
- [19] L. Panzella, F. Moccia, R. Nasti, S. Marzorati, L. Verotta, A. Napolitano, Bioactive Phenolic Compounds From Agri-Food Wastes: An Update on Green and Sustainable Extraction Methodologies, *Front Nutr* 7 (2020) 60.
- [20] K. Khosravi-Darani, E. Vasheghani-Farahani, Application of supercritical fluid extraction in biotechnology, *Crit Rev Biotechnol* 25(4) (2005) 231-42.
- [21] K.Y. Khaw, M.O. Parat, P.N. Shaw, J.R. Falconer, Solvent Supercritical Fluid Technologies to Extract Bioactive Compounds from Natural Sources: A Review, *Molecules* 22(7) (2017) 1186.
- [22] X. Zhao, D. Kim, G.G.D. Suminda, Y. Min, J. Yang, M. Kim, Y. Zhao, M. Ghosh, Y.-O. Son, Inhibitory effects of IL-6-mediated matrix metalloproteinase-3 and -13 by *Achyranthes japonica* Nakai root in osteoarthritis and rheumatoid arthritis mice models, *Pharmaceuticals* 14(8) (2021) 776.
- [23] D. Zhou, F. Zhou, J. Ma, F. Ge, Microcapsulation of *Ganoderma lucidum* spores oil: Evaluation of its fatty acids composition and enhancement of oxidative stability, *Industrial Crops and Products* 131 (2019) 1-7.
- [24] J.J. Inglis, G. Criado, M. Medghalchi, M. Andrews, A. Sandison, M. Feldmann, R.O. Williams, Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen, *Arthritis research & therapy* 9(5) (2007) 1-8.
- [25] D.D. Brand, K.A. Latham, E.F. Rosloniec, Collagen-induced arthritis, *Nature protocols*

2(5) (2007) 1269-1275.

[26] I. O-Sullivan, A. Natarajan Anbazhagan, G. Singh, K. Ma, S.J. Green, M. Singhal, J. Wang, A. Kumar, P.K. Dudeja, T.G. Unterman, *Lactobacillus acidophilus* Mitigates Osteoarthritis-Associated Pain, Cartilage Disintegration and Gut Microbiota Dysbiosis in an Experimental Murine OA Model, *Biomedicines* 10(6) (2022) 1298.

[27] J. Dzoyem, L. McGaw, V. Kuete, U. Bakowsky, *Anti-inflammatory and anti-nociceptive activities of African medicinal spices and vegetables, Medicinal spices and vegetables from Africa*, Elsevier2017, pp. 239-270.

[28] D.J. Langford, J.S. Mogil, *Pain testing in the laboratory mouse, Anesthesia and analgesia in laboratory animals*, Elsevier2008, pp. 549-560.

[29] P. Caplazi, M. Baca, K. Barck, R. Carano, J. DeVoss, W. Lee, B. Bolon, L. Diehl, *Mouse models of rheumatoid arthritis, Veterinary pathology* 52(5) (2015) 819-826.

[30] Y. Min, D. Kim, G.G.D. Suminda, X. Zhao, M. Kim, Y. Zhao, Y.-O. Son, *GSK5182, 4-Hydroxytamoxifen Analog, a New Potential Therapeutic Drug for Osteoarthritis, Pharmaceuticals* 13(12) (2020) 429.

[31] Y.-O. Son, S. Park, J.-S. Kwak, Y. Won, W.-S. Choi, J. Rhee, C.-H. Chun, J.-H. Ryu, D.-K. Kim, H.-S. Choi, *Estrogen-related receptor γ causes osteoarthritis by upregulating extracellular matrix-degrading enzymes, Nature communications* 8(1) (2017) 1-11.

[32] S.J. Kim, J. Kim, B. Kim, W.W. Lee, X. Liu, Y.T. Chang, J.W. Park, *Validation of CDr15 as a new dye for detecting neutrophil extracellular trap, Biochem Biophys Res Commun* 527(3) (2020) 646-653.

[33] X. Zhao, D. Kim, G.G.D. Suminda, Y. Min, J. Yang, M. Kim, Y. Zhao, M. Ghosh, Y.O. Son, *Inhibitory Effects of IL-6-Mediated Matrix Metalloproteinase-3 and -13 by *Achyranthes japonica* Nakai Root in Osteoarthritis and Rheumatoid Arthritis Mice Models, Pharmaceuticals (Basel)* 14(8) (2021).

[34] Y. Min, D. Kim, G.G.D. Suminda, X. Zhao, M. Kim, Y. Zhao, Y.O. Son, *GSK5182, 4-Hydroxytamoxifen Analog, a New Potential Therapeutic Drug for Osteoarthritis, Pharmaceuticals (Basel)* 13(12) (2020).

[35] J.M. Escandell, M.C. Recio, S. Máñez, R.M. Giner, M. Cerdá-Nicolás, J.L. Ríos, *Cucurbitacin R reduces the inflammation and bone damage associated with adjuvant arthritis in Lewis rats by suppression of tumor necrosis factor- α in T lymphocytes and macrophages, Journal of Pharmacology and Experimental Therapeutics* 320(2) (2007) 581-590.

[36] E.H. Choy, G.S. Panayi, *Cytokine pathways and joint inflammation in rheumatoid arthritis, New England Journal of Medicine* 344(12) (2001) 907-916.

- [37] J.J. Lee, Treatment Guidelines for Rheumatoid Arthritis, *Korean Journal of Medicine* 97(2) 93-98.
- [38] Z. Lin, Ganoderma (Lingzhi) in Traditional Chinese Medicine and Chinese Culture, *Adv Exp Med Biol* 1181 (2019) 1-13.
- [39] X. Liu, S.P. Xu, J.H. Wang, J.P. Yuan, L.X. Guo, X. Li, X.N. Huang, Characterization of ganoderma spore lipid by stable carbon isotope analysis: implications for authentication, *Anal Bioanal Chem* 388(3) (2007) 723-31.
- [40] H. Sales-Campos, P.R. Souza, B.C. Peghini, J.S. da Silva, C.R. Cardoso, An overview of the modulatory effects of oleic acid in health and disease, *Mini Rev Med Chem* 13(2) (2013) 201-10.
- [41] T.W. Kim, K.K. Kim, Y.H. Kang, D.J. Kim, M. Choe, Fatty acid analysis and regulatory effects of citron (*Citrus junos* Sieb. ex TANAKA) seed oil on nitric oxide production, lipid accumulation, and leptin secretion, *Journal of Nutrition and Health* 47(4) (2014) 221-228.
- [42] C. Carrillo Pérez, M.d.M. Cavia Camarero, S. Alonso de la Torre, Role of oleic acid in immune system; mechanism of action; a review, *Nutrición Hospitalaria*, 2012, v. 27, n. 4 (julio-agosto), p. 978-990 (2012).
- [43] C. Carrillo, M. Cavia Mdel, S. Alonso-Torre, Role of oleic acid in immune system; mechanism of action; a review, *Nutr Hosp* 27(4) (2012) 978-90.
- [44] I.B. McInnes, C.D. Buckley, J.D. Isaacs, Cytokines in rheumatoid arthritis — shaping the immunological landscape, *Nature Reviews Rheumatology* 12(1) (2016) 63-68.
- [45] E.G. Favalli, Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis, *Rheumatology and Therapy* 7(3) (2020) 473-516.
- [46] S. Srirangan, E.H. Choy, The role of interleukin 6 in the pathophysiology of rheumatoid arthritis, *The Adv Musculoskelet Dis* 2(5) (2010) 247-56.
- [47] F. Sofi, A. Parrey, M. Ahmad, Eosinophilia in rheumatoid arthritis patients and its relation to disease activity: a single center experience from Kashmir, India, *The Egyptian Rheumatologist* 39(2) (2017) 65-67.
- [48] H.K. Min, K.-W. Kim, S.-H. Lee, H.-R. Kim, Roles of mast cells in rheumatoid arthritis, *The Korean journal of internal medicine* 35(1) (2020) 12.
- [49] M.H. Abdel Meguid, Y.H. Hamad, R.S. Swilam, M.S. Barakat, Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage, *Rheumatology International* 33(3) (2013) 697-703.
- [50] V. Strand, S.H. Boklage, T. Kimura, F. Joly, A. Boyapati, J. Msihid, High levels of

interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab, *Arthritis research & therapy* 22(1) (2020) 250.

[51] M. Narazaki, T. Kishimoto, The Two-Faced Cytokine IL-6 in Host Defense and Diseases, *International journal of molecular sciences* 19(11) (2018).

[52] M. Jarlborg, C. Gabay, Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints, *Cytokine* 149 (2022) 155742.

[53] E.H. Choy, F. De Benedetti, T. Takeuchi, M. Hashizume, M.R. John, T. Kishimoto, Translating IL-6 biology into effective treatments, *Nature Reviews Rheumatology* 16(6) (2020) 335-345.

[54] M. Dougados, M. Soubrier, A. Antunez, P. Balint, A. Balsa, M.H. Buch, G. Casado, J. Detert, B. El-Zorkany, P. Emery, N. Hajjaj-Hassouni, M. Harigai, S.F. Luo, R. Kurucz, G. Maciel, E.M. Mola, C.M. Montecucco, I. McInnes, H. Radner, J.S. Smolen, Y.W. Song, H.E. Vonkeman, K. Winthrop, J. Kay, Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA), *Annals of the rheumatic diseases* 73(1) (2014) 62-8.

감사의 글

대학원에 입학한지 얼마 되지 않은 것 같은데 벌써 시간이 흘러 이 글을 쓰게 되는 날이 왔습니다. 대학원 진학 결정이 늦어져 급하게 준비를 하면서 잘 할 수 있을까 라는 생각과 함께 많은 걱정을 안고 시작했지만 주위의 많은 도움을 받아 이렇게 졸업까지 올 수 있게 되었습니다. 대학원을 진학하고 실험을 배우면서 실수도 많이 하고 알아가면 알아갈수록 모르는 것도 많아지면서 포기하고 싶은 생각도 했었지만 지금 생각해보면 그런 모든 순간들을 통해 이렇게 처음보다 성장할 수 있었던 것 같습니다. 이런 시간들을 지나오면서 주변에 감사한 분들이 정말 많았는데 가장 먼저 학기말에 무턱대고 찾아와서 대학원 가고 싶은데 실험실 들어가고 싶다고 했던 저를 거두어 주신 손영옥 지도교수님께 감사합니다. 항상 저희 뒤편까지 생각하며 챙겨주시고 아무것도 모르는 저를 데리고 실수해도 타박 보다는 알맞은 방법을 알려주시며 ‘다음에는 제대로 하면 되지’라고 격려해주셔서 자책을 하면서도 포기하지 않고 다시 일어서서 이렇게 논문을 잘 마무리 할 수 있었습니다. 또한 바쁘신 와중에도 논문에 대한 피드백과 심사를 해주신 도경탁 교수님과 강인혜 교수님 정말 감사드립니다.

2년의 과정 동안 끝까지 함께하지는 못했지만 계시는 동안 기본적인 질문 하나도 자세하게 알려주셨던 김다혜 박사님과 논문 쓰는데 있어 엄청난 필력으로 도와주신 Prof. Goash, 잘 안되는 영어로 물어봐도 찰떡같이 알아듣고 대화해준 Suminda, 처음 해보는 모든 실험들을 하나하나 알려주며 모르는게 있으면 언제든지 알려줬던 우리 실험실에 없어서는 안되는 윤희언니, 다른 실험실을 오가면서 바쁘지만 실험에 대한 팁과 알게 된 정보를 공유해준 지원언니, 같이 있으면 항상 장난도 많이 치고 실험실 물품 찾을 때 마다 도움 주고 힘쓰는 일을 도맡아준 한 때는 막내였던 우리 만근이 그리고 학부생 신분으로 수업도 많은데 실험실 일 까지 잘해 준 우리 민혜랑 명연이까지 동물유전공학 실험실 멤버들 덕분에 잘 마무리 할 수 있었습니다. 또 먼저 졸업하고 떠났지만 괴롭히면서도 잘 챙겨줬던 동균오빠 고마워!

대학교 와서 만난 갑자기 연락해도 항상 받아주고 힘들 때 마다 고민 들어줬던 소중한 인연 아샷추멤버들!! 주용오빠, 규현오빠, 상원오빠, 찬이오빠 그리고 힘들 때 내편이 되어준 민희, 하영이, 지윤이, 정연이 모두 너무 고마워! 다 적지는 못했지만 덕분에 무사히 대학원생활을 마칠 수 있었습니다. 그리고 맨날 짜증만 부리는 딸 공부하는데 있어 가장 많은 도움과 격려를 해주고 뒤에서 든든한 버팀목이 되어준 엄마, 아빠! 더 열심히 해서 자랑스러운 딸이 될게요. 항상 고맙고 사랑합니다. 평소에 표현하지 않지만 나를 응원해주고 지지해주는 친구 같은 은숙언니, 주원언니 그리고 화만 내는 누나, 언니 말 잘들어주는 준석이, 재연이. 또 잘 챙겨줬던 이모, 이모부, 큰형부와 작은형부 그리고 보는것만으로도 힘이 되었던 이원준 항상 고마워!

끝으로 처음이라 힘들었던 이 과정들이 지금은 모두 좋은 추억과 경험으로 남을 수 있게 해준 분들께 다시 한번 감사드립니다.

2022년 12월

허윤지